Short Term Trading New Year: 27 Dec - 1 Jan, page-24

sorry guys...

2019tip PIQ

bio-tech that signed collaboration agreement with US big pharma to accelerate diabetic kidney disease & heart disease drug discovery using PromarkerD

 PromarkerD is the world's first commercial test for predicting the onset of diabetic kidney disease

 Production of the new PromarkerD kit completed and first commercial batches to ship on 20 November, 2018 

The new PromarkerD immunoassay kit can be used by pathology laboratories globally, expanding the addressable market for PromarkerD significantly

 More licensing deals expected as the PromarkerD immunoassay kit opens up further commercialisation opportunities in Japan, India, and around the world

 Positive verification results on the PromarkerD immunoassay kit will be presented today at the 18th Annual Diabetes Technology Meeting, North Bethesda, USA

 There are currently 425 million adults globally with diabetes, and one in three already have diabetic kidney disease which may have been preventable by PromarkerD testing  PromarkerD could save the US healthcare system alone up to USD100 billion per year in direct costs associated with treating end-stage kidney disease

  PromarkerD mass spectrometry “Laboratory Developed Test” (LDT) has already been licensed in USA, Mexico and Spain

MC 30 million

hope that helps